+86 16650237703
Author:Kangdi 27-08-2026
1. 4 Sourcing Dimension Comparisons
Active Ingredients: Pain patches use menthol 3-16%, capsaicin 0.025-0.1%, lidocaine 4-5%, methyl salicylate 10-30% under FDA 21 CFR 348 OTC monograph. Heat patches use iron powder + activated carbon + salt + water (no API), cosmetic or general merchandise.
Regulatory Pathways: Pain patches need US OTC monograph + EU MDR Class IIa + GCC SFDA + NMPA. 4-8 weeks (US) to 12-24 months (China). USD 5,000-150,000+. Heat patches: cosmetic registration (US MoCRA + EU 1223/2009). 4-12 weeks. USD 2,000-15,000.
Manufacturing Processes: Pain patches need pharmaceutical-grade cleanroom (Class 10,000+), HPLC assay + USP 61. Heat patches need Class 100,000 cleanroom, iron-powder pouch assembly, basic QC.
End-User Segments: Pain patches target chronic pain (arthritis, fibromyalgia), sports medicine. Heat patches target cold-weather comfort, menstrual cramps, sleep aid. Customer overlap 40-60%. Pain patch USD 0.30-0.80 OEM FOB, heat patch USD 0.15-0.40 OEM FOB.
2. Decision Tree
Pain Patch Only if: (1) chronic pain / sports medicine / arthritis target market. (2) premium positioning (USD 18-35 retail). (3) regulatory handles FDA OTC monograph + EU MDR Class IIa. (4) MOQ USD 30,000+ first PO. Best for established OTC brands.
Heat Patch Only if: (1) cold-weather comfort / general wellness / menstrual / sleep aid target market. (2) value-tier (USD 8-15 retail). (3) cosmetic classification accepted. (4) MOQ USD 10,000-20,000 first PO. Best for private label mass-market.
Dual Category if: (1) complete thermotherapy portfolio. (2) channels carry both. (3) supplier qualification audits one factory for both lines. (4) MOQ USD 50,000+ combined. (5) customer cross-sell in place. Best for medium-to-large B2B distributors.
3. 4 Risk Mitigation Strategies
Risk 1 — GMP Compliance Gap: Pain patch needs pharmaceutical-grade GMP per 21 CFR 210/211. Heat patch does not. Same factory must prevent cross-contamination. Mitigation: segregated production areas + cleaning validation + annual audit.
Risk 2 — MOQ Inflation: Dual-category MOQ is 1.5-2x single-category. Mitigation: negotiate pilot run with lower MOQ per category (30,000 pain + 50,000 heat instead of 50,000 + 100,000) + commit to 3-6 month scaling.
Risk 3 — Inventory Imbalance: Pain patches 24-month shelf life, heat patches 36-month but seasonal winter spikes. Mitigation: 60% safety stock + 40% rolling forecast + JIT for seasonal SKUs.
Risk 4 — Customer Confusion: Retail buyers may not understand the difference. Mitigation: clear naming + distinct packaging color + separate SKU codes.
4. FAQ (4 Questions)
FAQ 1 — Single factory for both: Yes. Validation: (1) pharmaceutical-grade GMP (ISO 13485 + 21 CFR 210/211) for pain + cosmetic certification for heat. (2) Segregated production areas. (3) Separate quality agreements per line.
FAQ 2 — Combined MOQ: USD 50,000-150,000 first PO. Split: pain 30,000-50,000 + heat 50,000-100,000 units. Pilot run: 20,000 pain + 30,000 heat (USD 30,000-50,000). Henan Kangdi supports dual-category MOQ from USD 30,000 combined.
FAQ 3 — Positioning: Pain patch premium (USD 18-35 retail) for chronic pain / sports. Heat patch value (USD 8-15 retail) for warmth / wellness. Distinct packaging (pain white + blue / green, heat red + orange). Channel split: pain pharmacy + sports store, heat supermarket + convenience + online.
FAQ 4 — Margin: Pain USD 0.30-0.80 OEM FOB, retail USD 1.8-3.5 per patch, 70-85% markup. Heat USD 0.15-0.40 OEM FOB, retail USD 0.8-2.0 per patch, 60-75% markup. Pain higher margin but higher MOQ + longer timeline. Heat faster time-to-market. Blended 65-80%.
Contact: kangdimedical@gmail.com / +86 155 1754 1011. Updated: August 2026. Verify current FDA OTC monograph, EU MDR Class IIa, and country-specific registration before finalizing dual-category sourcing strategy.